Affiliation:
1. Institute of Medical Information & Library, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100020, China
Abstract
As China has undergone a new round of healthcare reforms since 2009, the drug sector has been subjected to a series of reform measures that aim to ensure a sustainable supply of drugs with controlled expenditures. This paper presents a bibliometric analysis of policy documents for the purpose of exploring the approaches within China’s drug reform. The analysis reveals that the National Health Commission (NHC) is the leading department of China’s drug reform, demonstrating that the core objective of drug reform is to ensure drug supply meets healthcare needs. The reform has evolved from its initial stage to the deepening and adjusting stage, with policy instruments becoming more interactive and involving greater numbers of implementers. Along with supply, drug quality and safety are the top concerns of the drug reform, followed by drug accessibility and affordability. Rational drug use is receiving greater attention in the deepening and adjusting stage. Environmental and demand-side instruments are being used more frequently in policies, while the utilization of supply-side instruments shows the opposite trend. Government departments at all levels play crucial roles in policy instrument implementation, with the significance of this function increasing. The participation of consumers in policy implementation is also rising. While medical institutions and enterprises are important implementers, their role is diminishing.
Funder
CAMS Innovation Fund for Medical Sciences
Subject
Management, Monitoring, Policy and Law,Renewable Energy, Sustainability and the Environment,Geography, Planning and Development,Building and Construction
Reference67 articles.
1. What can we learn from China’s health system reform?;Meng;BMJ Br. Med. J.,2019
2. (2023, April 06). The State Council of People Republic of China, Available online: http://www.gov.cn/jrzg/2009-04/06/content_1278721.htm.
3. Sun, J., Hu, C.J., Stuntz, M., Hogerzeil, H., and Liu, Y. (2018). A Review of Promoting Access to Medicines in China—Problems and Recommendations. BMC Health Serv. Res., 18.
4. Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls;Chen;Front. Pharmacol.,2021
5. “4 + 7” City Drug Volume-Based Purchasing and Using Pilot Program in China and its Impact;Tang;Drug Discov. Ther.,2019